Ryan S Anderton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7453208/publications.pdf

Version: 2024-02-01

		394421	477307
69	1,240	19	29
papers	citations	h-index	g-index

72	72	72	1288
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ACTN3 (R577X) Genotype Is Associated With Australian Football League Players. Journal of Strength and Conditioning Research, 2022, 36, 573-576.	2.1	4
2	Short structural variants as informative genetic markers for ALS disease risk and progression. BMC Medicine, 2022, 20, 11.	5.5	4
3	Changes in the rodent gut microbiome following chronic restraint stress and low-intensity rTMS. Neurobiology of Stress, 2022, 17, 100430.	4.0	15
4	Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Caseâ€“Control Study in an Australian Cohort. Movement Disorders Clinical Practice, 2021, 8, 245-253.	1.5	16
5	Differential effects of sex on longitudinal patterns of cognitive decline in Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1903-1912.	3.6	21
6	Association of Genetic Variances in ADRB1 and PPARGC1a with Two-Kilometre Running Time-Trial Performance in Australian Football League Players: A Preliminary Study. Sports, 2021, 9, 22.	1.7	2
7	Flexible Teaching and Learning Modalities in Undergraduate Science Amid the COVID-19 Pandemic. Frontiers in Education, 2021, 5, .	2.1	14
8	Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat. Neurochemical Research, 2021, 46, 1166-1176.	3.3	3
9	Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience, 2021, 13, 658226.	3.4	38
10	The TOMM40 â€˜523â€™ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 6363.	3.3	6
11	Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 656623.	3.4	7
12	TOMM40 â€˜523â€™ poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 56.	5.3	2
13	Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinsonâ€™s Disease Cohort. Frontiers in Neuroscience, 2021, 15, 756951.	2.8	15
14	TLR2 and TLR4 in Parkinsonâ€™s disease pathogenesis: the environment takes a toll on the gut. Translational Neurodegeneration, 2021, 10, 47.	8.0	40
15	In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Molecular and Cellular Biochemistry, 2020, 464, 27-38.	3.1	5
16	Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke Model. Neurotherapeutics, 2020, 17, 627-634.	4.4	21
17	An Investigation of Secondary School STEM Subjects as Predictors of Academic Performance in Tertiary Level Health Sciences Programs. International Journal of Higher Education, 2020, 10, 76.	0.5	2
18	Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort. Neurology: Genetics, 2020, 6, e470.	1.9	9

#	Article	IF	Citations
19	Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease. Frontiers in Aging Neuroscience, 2020, 12, 603849.	3.4	16
20	Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinsonâ€™s Disease. Parkinson's Disease, 2020, 2020, 1-7.	1.1	2
21	Effect of Polyarginine Peptide R18D Following a Traumatic Brain Injury in Sprague-Dawley Rats. Current Therapeutic Research, 2020, 92, 100584.	1.2	4
22	Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis. Neurology: Genetics, 2020, 6, e406.	1.9	9
23	Tissue distribution of intravenously administrated poly-arginine peptide R18D in healthy male Sprague–Dawley rats. Future Drug Discovery, 2020, 2, .	2.1	0
24	Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D. Neurochemical Research, 2020, 45, 1215-1229.	3.3	6
25	Poly-arginine-18 (R18) Confers Neuroprotection through Glutamate Receptor Modulation, Intracellular Calcium Reduction, and Preservation of Mitochondrial Function. Molecules, 2020, 25, 2977.	3.8	2
26	Structural Variants May Be a Source of Missing Heritability in sALS. Frontiers in Neuroscience, 2020, 14, 47.	2.8	43
27	The gut-brain axis and gut inflammation in Parkinsonâ€™s disease: stopping neurodegeneration at the toll gate. Expert Opinion on Therapeutic Targets, 2020, 24, 601-604.	3.4	12
28	Clinically assessing cognitive function in Parkinson's disease. , 2020, , 409-423.		2
29	The role of the gastrointestinal system and gut microbiota in Parkinson's disease. , 2020, , 569-582.		1
30	Altered Gut Microbiome in Parkinsonâ€™s Disease and the Influence of Lipopolysaccharide in a Human Î±-Synuclein Over-Expressing Mouse Model. Frontiers in Neuroscience, 2019, 13, 839.	2.8	122
31	Proteomic analysis of cortical neuronal cultures treated with poly-arginine peptide-18 (R18) and exposed to glutamic acid excitotoxicity. Molecular Brain, 2019, 12, 66.	2.6	6
32	Poly-arginine Peptide R18D Reduces Neuroinflammation and Functional Deficits Following Traumatic Brain Injury in the Long-Evans Rat. International Journal of Peptide Research and Therapeutics, 2019, 25, 1563-1572.	1.9	10
33	Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinsonâ€™s Disease Cohort. Parkinson's Disease, 2019, 2019, 1-6.	1.1	4
34	Microglia are both a source and target of extracellular cyclophilin A. Heliyon, 2019, 5, e02390.	3.2	7
35	Elevated Serum Homocysteine Levels Have Differential Gender-Specific Associations with Motor and Cognitive States in Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-8.	1.1	25
36	Tertiary Anatomy and Physiology, A Barrier for Student Success. International Journal of Higher Education, 2019, 9, 289.	0.5	7

#	Article	IF	Citations
37	Mitochondria and neuroprotection in stroke: Cationic arginine-rich peptides (CARPs) as a novel class of mitochondria-targeted neuroprotective therapeutics. Neurobiology of Disease, 2019, 121, 17-33.	4.4	37
38	Genetic predictors of match performance in sub-elite Australian football players: A pilot study. Journal of Exercise Science and Fitness, 2019, 17, 41-46.	2.2	12
39	The Potential Role of Genetic Markers in Talent Identification and Athlete Assessment in Elite Sport. Sports, 2018, 6, 88.	1.7	25
40	Assessment of therapeutic window for polyâ€arginineâ€18D (R18D) in a P7 rat model of perinatal hypoxicâ€ischaemic encephalopathy. Journal of Neuroscience Research, 2018, 96, 1816-1826.	2.9	12
41	Demographic and Clinical Predictors of Trait Impulsivity in Parkinsonâ€™s Disease Patients. Parkinson's Disease, 2018, 2018, 1-7.	1.1	12
42	Identification of genetic markers for skill and athleticism in sub-elite Australian football players: a pilot study. Journal of Sports Medicine and Physical Fitness, 2018, 58, 241-248.	0.7	13
43	Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Molecular Brain, 2018, 11, 8.	2.6	26
44	Perinatal Hypoxic-Ischemic Encephalopathy and Neuroprotective Peptide Therapies: A Case for Cationic Arginine-Rich Peptides (CARPs). Brain Sciences, 2018, 8, 147.	2.3	20
45	Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PLoS ONE, 2018, 13, e0193884.	2.5	26
46	Extended â€œTimed Up and Goâ€•assessment as a clinical indicator of cognitive state in Parkinson's disease. Journal of the Neurological Sciences, 2017, 375, 86-91.	0.6	17
47	The Neuroprotective Peptide Poly-Arginine-12 (R12) Reduces Cell Surface Levels of NMDA NR2B Receptor Subunit in Cortical Neurons; Investigation into the Involvement of Endocytic Mechanisms. Journal of Molecular Neuroscience, 2017, 61, 235-246.	2.3	39
48	Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginineâ€“Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats. NeuroMolecular Medicine, 2017, 19, 271-285.	3.4	37
49	Delayed 2-h post-stroke administration of R18 and NA-1 (TAT-NR2B9c) peptides after permanent and/or transient middle cerebral artery occlusion in the rat. Brain Research Bulletin, 2017, 135, 62-68.	3.0	11
50	Identifying factors that contribute to academic success in first year allied health and science degrees at an Australian University. Australian Journal of Education, 2017, 61, 184-199.	1.5	14
51	Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury. Translational Neuroscience, 2017, 8, 147-157.	1.4	28
52	Modification to the Rice-Vannucci perinatal hypoxic-ischaemic encephalopathy model in the P7 rat improves the reliability of cerebral infarct development after 48 hours. Journal of Neuroscience Methods, 2017, 288, 62-71.	2.5	28
53	Characterisation of neuroprotective efficacy of modified poly-arginine-9 (R9) peptides using a neuronal glutamic acid excitotoxicity model. Molecular and Cellular Biochemistry, 2017, 426, 75-85.	3.1	21
54	Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides. Molecular Neurobiology, 2017, 54, 7838-7857.	4.0	11

#	Article	IF	Citations
55	Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neuroscience Research, 2017, 114, 9-15.	1.9	49
56	Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinsonâ€™s Disease Patients. American Journal of Psychiatry and Neuroscience, 2017, 5, 45.	0.1	2
57	Lack of Evidence for Decreased Protein Stability in the 2397 (Met) Haplotype of the Leucine Rich Repeat Kinase 2 Protein Implicated in Parkinsonâ€™s Disease. Advances in Parkinson S Disease, 2017, 06, 113-123.	0.2	0
58	Student Perceptions to Teaching Undergraduate Anatomy in Health Sciences. International Journal of Higher Education, 2016, 5, .	0.5	8
59	The neuroprotective potential of arginine-rich peptides for the acute treatment of traumatic brain injury. Expert Review of Neurotherapeutics, 2016, 16, 361-363.	2.8	14
60	Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model. BMC Neuroscience, 2016, 17, 19.	1.9	35
61	Predicting Academic Success of Health Science Students for First Year Anatomy and Physiology. International Journal of Higher Education, 2015, 5, .	0.5	24
62	Poly-Arginine and Arginine-Rich Peptides are Neuroprotective in Stroke Models. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 993-1004.	4.3	78
63	Neuroprotective peptides fused to arginine-rich cell penetrating peptides: Neuroprotective mechanism likely mediated by peptide endocytic properties. , 2015, 153, 36-54.		71
64	Advances and challenges in developing a therapy for spinal muscular atrophy. Expert Review of Neurotherapeutics, 2015, 15, 895-908.	2.8	8
65	Investigation of a recombinant SMN protein delivery system to treat spinal muscular atrophy. Translational Neuroscience, 2014, 5, .	1.4	3
66	Is Cholesterol and Amyloid-Î² Stress Induced CD147 Expression a Protective Response? Evidence that Extracellular Cyclophilin A Mediated Neuroprotection is Reliant on CD147. Journal of Alzheimer's Disease, 2014, 39, 545-556.	2.6	11
67	Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein. Molecular Neurobiology, 2013, 47, 821-832.	4.0	20
68	Co-regulation of survival of motor neuron and Bcl-xL expression: Implications for neuroprotection in spinal muscular atrophy. Neuroscience, 2012, 220, 228-236.	2.3	15
69	Survival of motor neuron protein over-expression prevents calpain-mediated cleavage and activation of procaspase-3 in differentiated human SH-SY5Y cells. Neuroscience, 2011, 181, 226-233.	2.3	11